{"filing":{"accession_number":"0001193125-26-376733","cik":"0001612042","ticker":"ASND","company_name":"Ascendis Pharma A/S","form":"6-K","filing_date":"2026-08-31","report_date":"2026-08-31","primary_document":"d139239d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1612042/000119312526376733/d139239d6k.htm"},"events":[{"id":30605,"run_id":28056,"accession_number":"0001193125-26-376733","anchor_item_number":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"The 6-K discloses that Ascendis Pharma has entered into a binding term sheet with BioMarin Pharmaceutical for a global settlement and license agreement related to the sale of YUVIWEL® and navepegritide-related products. The agreement resolves all litigation and disputes, grants Ascendis a non-exclusive worldwide royalty-bearing license to continue developing and commercializing navepegritide products, and establishes royalty payment obligations (20% in the US, 18% in EU/South Korea/Brazil through May 2030). This constitutes a material transaction involving intellectual property rights, product commercialization rights, and settlement of disputes that would materially affect investor assessment of the company's product portfolio and financial obligations.","company_name":"Ascendis Pharma A/S","ticker":"ASND","filing_date":"2026-08-31","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":33251,"accession_number":"0001193125-26-376733","item_number":null,"item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The 6-K discloses that Ascendis Pharma has entered into a binding term sheet with BioMarin Pharmaceutical for a global settlement and license agreement related to the sale of YUVIWEL® and navepegritide-related products. The agreement resolves all litigation and disputes, grants Ascendis a non-exclusive worldwide royalty-bearing license to continue developing and commercializing navepegritide products, and establishes royalty payment obligations (20% in the US, 18% in EU/South Korea/Brazil through May 2030). This constitutes a material transaction involving intellectual property rights, product commercialization rights, and settlement of disputes that would materially affect investor assessment of the company's product portfolio and financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T20:13:51.023123+00:00","company_name":"Ascendis Pharma A/S","ticker":"ASND","filing_date":"2026-08-31"}]}